Immunotherapy Rechallenge in NSCLC Yields Overall Survival Boost

Phase II trial sees 'synergistic benefit' with checkpoint blockade and anti-angiogenesis

Related Keywords

United States ,University Of Chicago ,Illinois ,Chicago ,American ,Christine Bestvina ,Los Angeles ,Karen Reckamp ,Sinai Medical Center ,American Society Of Clinical Oncology ,University Of Chicago Comprehensive Cancer Center ,Eastern Cooperative Oncology Group ,Cedars Sinai Medical Center ,American Society ,Clinical Oncology ,Chicago Comprehensive Cancer Center ,Managing Editor ,Medpage Today ,